Publications

Find at Harvard

June 2004
Case

Aventis SA (A): Planning for a Merger

By: Joshua D. Margolis and Carin-Isabel Knoop

Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details

Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States

February 2019 (Revised August 2019)
Case

Maccabitech: The Promise of Israel's Healthcare Data

By: Scott Duke Kominers and Carin-Isabel Knoop

Dr. Varda Shalev bridges technology and medicine through Maccabitech, a "research and innovation wing" of Israel's Maccabi Healthcare Services (MHS) that partners with research institutions, pharmaceutical companies, and startups. Shalev hopes to scale Maccabitech's... View Details

Keywords: Big Data; Healthcare; Analytics and Data Science; Digital Platforms; Health Care and Treatment; Innovation and Invention; Research; Entrepreneurship; Risk Management; Israel

February 1996
Case

Chadwick, Inc.: The Balanced Scorecard (Abridged)

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry

2018
Chapter

Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals

By: Juan Alcacer, John Cantwell and Michelle Gittelman

As the value chain of the pharmaceutical industry disaggregates, upstream discovery is increasingly carried out by small research-specialized firms while downstream development, testing and marketing is conducted by global pharmaceutical firms. Licensing plays an... View Details

Keywords: Geographic Location; Local Range; Rights; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry

11 Jan 2017
News

How do we solve the crisis in cancer communication?

January 1993 (Revised April 1993)
Case

Chadwick, Inc.: The Balanced Scorecard

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Performance Evaluation; Customer Relationship Management; Goals and Objectives; Customer Satisfaction; Research and Development; Marketplace Matching; Financial Condition; Product Launch; Pharmaceutical Industry

Research Summary

Overview

By: Kyle R. Myers

Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how... View Details

July 2010
Case

Metabical: Positioning and Communications Strategy for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham

Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details

Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States

May 2025
Case

Daiichi Sankyo: Steering a Global Organization

By: Tiona Zuzul, Amy C. Edmondson and Cat Huang

In the spring of 2023, Sunao Manabe, CEO of Daiichi Sankyo, reflected on a pivotal decision. A large Western pharmaceutical company had made a bid to partner with Daiichi Sankyo to develop the next three products in its oncology pipeline. Daiichi Sankyo, a 125-year old... View Details

Keywords: Strategy; Culture Change; Decision-making; Leadership; Culture; Innovation; Psychological Safety

March 2008
Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington

Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details

Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry

May 2021
Article

Private and Social Returns to R&D: Drug Development and Demographics

By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger

Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer... View Details

Keywords: Drug Development; Research and Development; Investment Return; Demographics; Pharmaceutical Industry

Find at Harvard

Register to Read

Research Summary

Entrepreneurial Finance and International R&D Management

Walter Kuemmerle's research and teaching interests fall within the domain of knowledge and capital management in a global economy. His research focuses on international entrepreneurship and venture capital. He studies venture capital systems and entrepreneurship in... View Details

September 1991 (Revised February 1993)
Case

Burroughs Wellcome and AZT (A)

By: Willis M. Emmons III

Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details

Keywords: Governing Rules, Regulations, and Reforms; Ethics; Business and Government Relations; Communication Strategy; Health Care and Treatment; Monopoly; Intellectual Property; Research and Development; Price; Pharmaceutical Industry; London

23 Mar 2003
Research & Ideas

AIDS in Africa—What’s the Solution?

according to panelists from the healthcare field and the pharmaceutical industry, is delivering drugs that are donated or available at reduced prices to patients who need them. Government Priorities Dr. Konji Sebati, a physician with the... View Details

Keywords: by Julie Jette

Leemore S. Dafny

Leemore Dafny is the Bruce V. Rauner Professor of Business Administration and the Mary Ellen Jay and Jeffrey Jay Fellow at the Harvard Business School, and Professor of Public Policy at the Harvard Kennedy School. Dafny is an applied microeconomist whose... View Details

Keywords: health care

28 Mar 2023
Research & Ideas

The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Jennifer Kao of the University of California, Los Angeles and the FDA’s Kathleen Miller are also coauthors. Speeding... View Details

Keywords: by Kasandra Brabaw; Pharmaceutical

2015
Working Paper

Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules

By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat

We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly... View Details

Keywords: Economics Of Science; Patenting; Academic Reserach; NIH; Knowledge Spillovers; Patents; Research; Government and Politics

Read Now

October 2023 (Revised April 2024)
Case

Accounting Red Flags or Red Herrings at Catalent? (A)

By: Joseph Pacelli, ZeSean Ali and Tom Quinn

Fund manager Janet Curie asked for a recommendation about the pharmaceutical company Catalent. The company seemed like a solid investment. However, a pair of research reports issued over the previous two months complicated this narrative. GlassHouse Research, a short... View Details